SCHEMBL2367945

SCHEMBL2367945

Cc1ccc(Oc2ccc3cccc4c3c2C(=O)C4=O)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.44
CES1 P23141 3/20 0.44
CES2 O00748 2/20 0.44
MCL1 Q07820 2/20 0.44
BCHE P06276 1/20 0.44
KDM4E B2RXH2 1/20 0.40
HPGD P15428 1/20 0.40
BCL2 P10415 1/20 0.39
SMN1; SMN2 Q16637 3/20 0.39
LMNA P02545 3/20 0.39
HTT P42858 3/20 0.38
MAPT P10636 2/20 0.38
MAPK1 P28482 2/20 0.38
KMT2A Q03164 2/20 0.38
TP53 P04637 1/20 0.38
POLB P06746 1/20 0.38
XBP1 P17861 1/20 0.38
HKDC1 Q2TB90 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
L3MBTL1 Q9Y468 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2367539 0.87 MAPT (0.49) ALDH1A1CES1CES2MCL1BCHE
SCHEMBL827965 0.79 MAPT (0.55) ALDH1A1CES1CES2MCL1BCHE
SCHEMBL15177181 0.78 MCL1 (0.58) ALDH1A1CES1CES2MCL1KDM4E
SCHEMBL2701449 0.73 ALDH1A1 (0.59) ALDH1A1CES1CES2MCL1BCHE
SCHEMBL11110221 0.73 CES2 (0.53) ALDH1A1CES1CES2KDM4ESMN1; SMN2
SCHEMBL11579521 0.70 SMN1; SMN2 (0.63) ALDH1A1CES1CES2MCL1KDM4E
SCHEMBL11581660 0.70 ADORA2A (0.51) ALDH1A1CES1CES2SMN1; SMN2LMNA
SCHEMBL2040632 0.69 PARP1 (0.53) CES1CES2KDM4ESMN1; SMN2LMNA
SCHEMBL11581548 0.69 ADORA2A (0.50) ALDH1A1CES1CES2SMN1; SMN2LMNA
SCHEMBL30420926 0.68 ALDH1A1 (0.61) ALDH1A1CES1CES2MCL1BCHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110251188-A1 ACENAPHTHO HETEROCYCLE COMPOUNDS, CYCLODEXTRIN INCLUSION COMPOUNDS AND COMPLEXES, AND USES IN THE MANUFACTURES OF BH3 PROTEIN ANALOGUE, BCL-2 FAMILY PROTEIN INHIBITORS THEREOF DALIAN UNIVERSITY OF TECHNOLOGY (CN) 2011-10-13 US disclosed
EP-2366701-A1 ACENAPHTHO HETEROCYCLE COMPOUNDS, CYCLODEXTRIN INCLUSION COMPOUNDS AND COMPLEXES, AND USES IN THE MANUFACTURES OF BH3 PROTEIN ANALOGUE, BCL-2 FAMILY PROTEIN INHIBITORS THEREOF Dalian University Of Technology (CN) 2011-09-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110251188-A1 ACENAPHTHO HETEROCYCLE COMPOUNDS, CYCLODEXTRIN INCLUSION COMPOUNDS AND COMPLEXES, AND USES IN THE MANUFACTURES OF BH3 PROTEIN ANALOGUE, BCL-2 FAMILY PROTEIN INHIBITORS THEREOF BID, BCL2, BAX ALDH1A1 3230/4885CES1 1148/4885CES2 1888/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.